Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pX330 p53 Citations (14)

Originally described in: CRISPR-mediated direct mutation of cancer genes in the mouse liver.
Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, Cai W, Yang G, Bronson R, Crowley DG, Zhang F, Anderson DG, Sharp PA, Jacks T Nature. 2014 Aug 6. doi: 10.1038/nature13589.
PubMed Journal

Articles Citing pX330 p53

Articles
A Mutant p53-Dependent Embryonic Stem Cell Gene Signature Is Associated with Augmented Tumorigenesis of Stem Cells. Koifman G, Shetzer Y, Eizenberger S, Solomon H, Rotkopf R, Molchadsky A, Lonetto G, Goldfinger N, Rotter V. Cancer Res. 2018 Oct 15;78(20):5833-5847. doi: 10.1158/0008-5472.CAN-18-0805. Epub 2018 Aug 28. PubMed
Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy. Lonetto G, Koifman G, Silberman A, Attery A, Solomon H, Levin-Zaidman S, Goldfinger N, Porat Z, Erez A, Rotter V. Cell Death Differ. 2018 Nov 9. pii: 10.1038/s41418-018-0227-z. doi: 10.1038/s41418-018-0227-z. PubMed
Inducing and exploiting vulnerabilities for the treatment of liver cancer. Wang C, Vegna S, Jin H, Benedict B, Lieftink C, Ramirez C, de Oliveira RL, Morris B, Gadiot J, Wang W, du Chatinier A, Wang L, Gao D, Evers B, Jin G, Xue Z, Schepers A, Jochems F, Sanchez AM, Mainardi S, Te Riele H, Beijersbergen RL, Qin W, Akkari L, Bernards R. Nature. 2019 Oct;574(7777):268-272. doi: 10.1038/s41586-019-1607-3. Epub 2019 Oct 2. PubMed
Loss of polycystins suppresses deciliation via the activation of the centrosomal integrity pathway. Gerakopoulos V, Ngo P, Tsiokas L. Life Sci Alliance. 2020 Jul 10;3(9). pii: 3/9/e202000750. doi: 10.26508/lsa.202000750. Print 2020 Sep. PubMed
EGFR activation limits the response of liver cancer to lenvatinib. Jin H, Shi Y, Lv Y, Yuan S, Ramirez CFA, Lieftink C, Wang L, Wang S, Wang C, Dias MH, Jochems F, Yang Y, Bosma A, Hijmans EM, de Groot MHP, Vegna S, Cui D, Zhou Y, Ling J, Wang H, Guo Y, Zheng X, Isima N, Wu H, Sun C, Beijersbergen RL, Akkari L, Zhou W, Zhai B, Qin W, Bernards R. Nature. 2021 Jul;595(7869):730-734. doi: 10.1038/s41586-021-03741-7. Epub 2021 Jul 21. PubMed
A novel murine model of combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Xu RC, Wang F, Sun JL, Abuduwaili W, Zhang GC, Liu ZY, Liu TT, Dong L, Shen XZ, Zhu JM. J Transl Med. 2022 Dec 9;20(1):579. doi: 10.1186/s12967-022-03791-z. PubMed
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma. Mulero-Sanchez A, Ramirez CFA, du Chatinier A, Wang H, Koomen SJI, Song JY, de Groot MHP, Lieftink C, Bosma A, Burylo A, van Tellingen O, Beijersbergen RL, Wang C, Akkari L, Bernards R, Mainardi S. Mol Oncol. 2023 Jun;17(6):964-980. doi: 10.1002/1878-0261.13377. Epub 2023 Feb 9. PubMed
Androgen receptor variant 7 exacerbates hepatocarcinogenesis in a c-MYC-driven mouse HCC model. Kido T, Lau YC. Oncogenesis. 2023 Feb 6;12(1):4. doi: 10.1038/s41389-023-00449-3. PubMed
CD36(+) cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Zhu GQ, Tang Z, Huang R, Qu WF, Fang Y, Yang R, Tao CY, Gao J, Wu XL, Sun HX, Zhou YF, Song SS, Ding ZB, Dai Z, Zhou J, Ye D, Wu DJ, Liu WR, Fan J, Shi YH. Cell Discov. 2023 Mar 6;9(1):25. doi: 10.1038/s41421-023-00529-z. PubMed
Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis. Zhou Y, Cui G, Xu H, Chun J, Yang D, Zhang Z, Yang L, Wang J, Wan M, Calvisi DF, Lin S, Chen X, Wang H. Cell Death Dis. 2023 Jul 27;14(7):476. doi: 10.1038/s41419-023-05958-y. PubMed
Low glucose metabolite 3-phosphoglycerate switches PHGDH from serine synthesis to p53 activation to control cell fate. Wu YQ, Zhang CS, Xiong J, Cai DQ, Wang CZ, Wang Y, Liu YH, Wang Y, Li Y, Wu J, Wu J, Lan B, Wang X, Chen S, Cao X, Wei X, Hu HH, Guo H, Yu Y, Ghafoor A, Xie C, Wu Y, Xu Z, Zhang C, Zhu M, Huang X, Sun X, Lin SY, Piao HL, Zhou J, Lin SC. Cell Res. 2023 Nov;33(11):835-850. doi: 10.1038/s41422-023-00874-4. Epub 2023 Sep 19. PubMed

Associated Plasmids

Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy. Ghasemi A, Martinez-Usatorre A, Li L, Hicham M, Guichard A, Marcone R, Fournier N, Torchia B, Martinez Bedoya D, Davanture S, Fernandez-Vaquero M, Fan C, Janzen J, Mohammadzadeh Y, Genolet R, Mansouri N, Wenes M, Migliorini D, Heikenwalder M, De Palma M. Nat Cancer. 2024 Feb;5(2):240-261. doi: 10.1038/s43018-023-00668-y. Epub 2023 Nov 23. PubMed
Blocking methionine catabolism induces senescence and confers vulnerability to GSK3 inhibition in liver cancer. Li F, Liu P, Mi W, Li L, Anderson NM, Lesner NP, Burrows M, Plesset J, Majer A, Wang G, Li J, Zhu L, Keith B, Simon MC. Nat Cancer. 2024 Jan;5(1):131-146. doi: 10.1038/s43018-023-00671-3. Epub 2024 Jan 2. PubMed
LncRNA CRNDE Drives the Progression of Hepatocellular Carcinoma by inducing the Immunosuppressive Niche. Li X, Liang S, Fei M, Ma K, Sun L, Liu Y, Liu L, Wang J. Int J Biol Sci. 2024 Jan 1;20(2):718-732. doi: 10.7150/ijbs.85471. eCollection 2024. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.